[go: up one dir, main page]

CL2008003036A1 - Aqueous pharmaceutical composition comprising 4 - [(4-chlorophenyl) methyl] -2 - ({(2r) -1- [4- (4 - {[3- (hexahydro-1h-azepin-1-yl) propyl] oxy } phenyl) butyl] -2-pyrrolidinyl} methyl) -1 (2h) -phthalazinone; container comprising it; and use for the treatment of inflammatory and / or allergic diseases such as allergic rhinitis. - Google Patents

Aqueous pharmaceutical composition comprising 4 - [(4-chlorophenyl) methyl] -2 - ({(2r) -1- [4- (4 - {[3- (hexahydro-1h-azepin-1-yl) propyl] oxy } phenyl) butyl] -2-pyrrolidinyl} methyl) -1 (2h) -phthalazinone; container comprising it; and use for the treatment of inflammatory and / or allergic diseases such as allergic rhinitis.

Info

Publication number
CL2008003036A1
CL2008003036A1 CL2008003036A CL2008003036A CL2008003036A1 CL 2008003036 A1 CL2008003036 A1 CL 2008003036A1 CL 2008003036 A CL2008003036 A CL 2008003036A CL 2008003036 A CL2008003036 A CL 2008003036A CL 2008003036 A1 CL2008003036 A1 CL 2008003036A1
Authority
CL
Chile
Prior art keywords
methyl
phthalazinone
azepin
hexahydro
pyrrolidinyl
Prior art date
Application number
CL2008003036A
Other languages
Spanish (es)
Inventor
Simon Teanby Hodgson
Ashley Paul Hancock
Leanda Jane Kindon
Gavin Bone
Richard Orlando Brown
Paul Martin Gore
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2008003036A1 publication Critical patent/CL2008003036A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica acuosa que comprende 4-[(4-clorofenil)metil]-2-({(2r)-1-[4-(4-{[3-(hexahidro-1h-azepin-1-il)propil]oxi}fenil)butil]-2-pirrolidinil}metil)-1(2h)-ftalazinona; envase que la comprende; y uso para el tratamiento de enfermedades inflamatorias y/o alérgicas tal como rinitis alérgica.Aqueous pharmaceutical composition comprising 4 - [(4-chlorophenyl) methyl] -2 - ({(2r) -1- [4- (4 - {[3- (hexahydro-1h-azepin-1-yl) propyl] oxy } phenyl) butyl] -2-pyrrolidinyl} methyl) -1 (2h) -phthalazinone; container comprising it; and use for the treatment of inflammatory and / or allergic diseases such as allergic rhinitis.

CL2008003036A 2007-10-16 2008-10-14 Aqueous pharmaceutical composition comprising 4 - [(4-chlorophenyl) methyl] -2 - ({(2r) -1- [4- (4 - {[3- (hexahydro-1h-azepin-1-yl) propyl] oxy } phenyl) butyl] -2-pyrrolidinyl} methyl) -1 (2h) -phthalazinone; container comprising it; and use for the treatment of inflammatory and / or allergic diseases such as allergic rhinitis. CL2008003036A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98022607P 2007-10-16 2007-10-16
US5723008P 2008-05-30 2008-05-30

Publications (1)

Publication Number Publication Date
CL2008003036A1 true CL2008003036A1 (en) 2009-05-08

Family

ID=40198721

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003036A CL2008003036A1 (en) 2007-10-16 2008-10-14 Aqueous pharmaceutical composition comprising 4 - [(4-chlorophenyl) methyl] -2 - ({(2r) -1- [4- (4 - {[3- (hexahydro-1h-azepin-1-yl) propyl] oxy } phenyl) butyl] -2-pyrrolidinyl} methyl) -1 (2h) -phthalazinone; container comprising it; and use for the treatment of inflammatory and / or allergic diseases such as allergic rhinitis.

Country Status (6)

Country Link
AR (1) AR068988A1 (en)
CL (1) CL2008003036A1 (en)
PE (1) PE20091089A1 (en)
TW (1) TW200932243A (en)
UY (1) UY31400A1 (en)
WO (1) WO2009050159A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811447D0 (en) * 2008-06-20 2008-07-30 Glaxo Group Ltd Formulations
JP6294893B2 (en) * 2012-12-17 2018-03-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Combination of levocabastine and fluticasone furan carboxylate to treat inflammatory and / or allergic conditions
EP4251148A1 (en) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
KR20090007604A (en) * 2006-04-20 2009-01-19 글락소 그룹 리미티드 2-substituted 4-benzylphthalazinone derivatives as histamine H1 and H3 antagonists

Also Published As

Publication number Publication date
AR068988A1 (en) 2009-12-23
TW200932243A (en) 2009-08-01
WO2009050159A1 (en) 2009-04-23
UY31400A1 (en) 2009-05-29
PE20091089A1 (en) 2009-08-24

Similar Documents

Publication Publication Date Title
CL2008000795A1 (en) USE OF 1- [2- (2,4-DIMETILFENILSULFANIL) PHENYL) PIPERAZINE FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS OF DEPRESSION; AND SUCH COMPOUND.
CL2011002781A1 (en) Compounds (e) -2- (4- (2- (5- (1- (3,5-dichloropyridin-4-yl) ethoxy) -1h-indazol-3-yl) vinyl) -1h-pyrazol-1- yl) ethanol and (r) - (e) -2- (4- (2- (5- (1- (3,5-dichloropyridin-4-yl) ethoxy) -1h-indazol-3-yl) vinyl) -1h-pyrazol-1-yl) ethanol; pharmaceutical composition comprising them; and use in the treatment of cancer.
CL2011002697A1 (en) Compounds derived from 3- [4- (oxo-dihydropyridin) benzyl] -1,3-oxazin-one hydrated, 11beta-hsd1 inhibitors; pharmaceutical composition comprising them; and its use in the treatment of diabetes
ATE516286T1 (en) 5-(Ä1,3,4ÜOXADIAZOLE-2-YL)-1H-INDAZOLE AND 5-(Ä1,3,4ÜTHIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES
CL2011001224A1 (en) Compounds derived from benzofuran-3-carboxamide; pharmaceutical composition that includes them; and its use in hepatitis C virus treatment.
MA34552B1 (en) CRYSTALLINE (R) - (E) -2- (4- (2- (5- (1- (3,5-DICHLOROPYRIDIN-4-yl) ETHOXY) -1H-INDAZOL-3-YL) VINYL) -1H - PYRAZOL-1-YL) ANDHANOL AND ITS USE AS FGFR INHIBITOR
CO6592093A2 (en) Polymorphs and solvates of 4- (2 - ((5-methyl-1- (2-naphthalenyl) -1h-pyrazol-3-yl) oxy9ethyl) morpholine hydrochloride
PE20100083A1 (en) DRUG COMBINATIONS INCLUDING A DGAT INHIBITOR AND A PPAR AGONIST
CU20110213A7 (en) DISACARINE SALTS, DIFUMARIC ACID, DI-1-HYDROXY-2-NAFTOIC ACID AND MONOBENZOIC ACID OF 2- (4 - ((2-AMINO-4-METHYL-6- (PENTILAMINO) PIRIMIDIN-5-IL) METHYL) ) ACETATE OF 4- (DIMETHYLAMINE) BUTILO
CL2008000796A1 (en) USE OF 4- (2- (4-METHYLPHENYL SULFANYL) PHENYL) PIPERIDINE AND ACID ADDITION SALTS OF THE SAME FOR THE TREATMENT OF ADHD, MELANCOLIA, DEPRESSION OR RESIDUAL SYMPTOMS OF DEPRESSION; AND SUCH COMPOUND.
CY1110026T1 (en) Piperazine benzisoxazole compounds and methods of use thereof
UA112055C2 (en) SALTS 4- [2 - [[5-METHYL-1- (2-NAPHTHALINYL) -1H-PYRAZOL-3-yl] OXY] ETHYL] MORPHOLINE
UY31431A1 (en) INHIBITOR OF THE 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP)
ATE534632T1 (en) THIAZOLES, IMIDAZOLES AND PYRAZOLES AS PROTEIN KINASE INHIBITORS
BRPI0815048A2 (en) phenoxy pyrrolidines derivative and use and compositions thereof
NZ594556A (en) Carboxamide compounds and methods for using the same
IT1391866B1 (en) INJECTIONABLE COMPOSITION OF POLYNUCLEOTIDS FOR THE TREATMENT OF OSTEOARTICULAR DISEASES.
SI2475368T1 (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
CL2007000595A1 (en) Piperidine derived compounds; Pharmaceutical composition and use for the treatment and / or prophylaxis of diseases selected from hypertension, congestive heart failure and renal failure, among others.
ATE401891T1 (en) USE OF MELOXICAM FORMULATIONS IN VETERINARY MEDICINE
CL2009000665A1 (en) Pyrrolidinyl derived compounds; pharmaceutical composition comprising said compounds; and its use in the treatment of anxiety, depression or both.
FR2901467B1 (en) ANATOMIC PROSTHESIS FOR THE TREATMENT OF HERNIA, SUCH AS INGUINAL AND CRURAL HERNIA AND OTHER
CL2008003036A1 (en) Aqueous pharmaceutical composition comprising 4 - [(4-chlorophenyl) methyl] -2 - ({(2r) -1- [4- (4 - {[3- (hexahydro-1h-azepin-1-yl) propyl] oxy } phenyl) butyl] -2-pyrrolidinyl} methyl) -1 (2h) -phthalazinone; container comprising it; and use for the treatment of inflammatory and / or allergic diseases such as allergic rhinitis.
MX2022007176A (en) 4-((2-OXOPYRI DIN-1 (2H)-YL)METHYL)BENZAMIDES FOR THE TREATMENT OF ALPHA1-ANTYTRIPSIN DEFICIENCY.
EP3845528C0 (en) PYRAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE AS IRAK4 INHIBITORS